You are viewing an incomplete version of our website. Please click to reload the website as full version.

NOTCH3 antibody (Notch 3) (C-Term)

Details for Product anti-NOTCH3 Antibody No. ABIN966682, Supplier: Log in to see
Antigen
  • AW229011
  • CADASIL
  • CASIL
  • fa14b08
  • hpbk
  • IMF2
  • N3
  • notch5
  • wu:fa14b08
Alternatives
anti-Human NOTCH3 antibody for ELISA
Epitope
C-Term
64
11
9
7
7
7
7
5
5
3
3
2
2
2
1
1
Reactivity
Human
167
45
22
3
2
1
1
1
Host
Rabbit
85
62
22
15
3
2
2
Clonality
Polyclonal
Conjugate
This NOTCH3 antibody is un-conjugated
14
13
6
6
6
5
4
4
3
3
3
2
2
2
2
2
2
2
2
2
1
1
1
Application
Immunohistochemistry (IHC)
103
103
77
49
11
11
5
4
3
1
1
1
Supplier
Log in to see
Supplier Product No.
Log in to see
Request

Get this product for free

It's quick and easy to submit your validation proposal. I want to validate this product

Learn more

Immunogen Polyclonal antibody produced in rabbits immunizing with a synthetic peptide corresponding to C-terminal residues of human NOTCH3 (Neurogenic locus notch homolog protein 3)
Alternative Name NOTCH3 (NOTCH3 Antibody Abstract)
Background NOTCH3 (Neurogenic locus notch homolog protein 3) functions as a receptor for membrane-bound ligands Jagged1, Jagged2 and Delta1 to regulate cell-fate determination. Upon ligand activation through the released notch intracellular domain (NICD) it forms a transcriptional activator complex with RBP-J kappa and activates genes of the enhancer of split locus. NOTCH3 affects the implementation of differentiation, proliferation and apoptotic programs. NOTCH3 is a heterodimer of a C-terminal fragment N(TM) and a N-terminal fragment N(EC) which are probably linked by disulfide bonds. NOTCH3 interacts with MAML1, MAML2 and MAML3 which act as transcriptional coactivators for NOTCH3. NOTCH3 is ubiquitously expressed in fetal and adult tissues. It is synthesized in the endoplasmic reticulum as an inactive form which is proteolytically cleaved by a furin-like convertase in the trans-Golgi network before it reaches the plasma membrane to yield an active, ligand-accessible form. Cleavage results in a C-terminal fragment N(TM) and a N-terminal fragment N(EC). Following ligand binding, it is cleaved by TNF-alpha converting enzyme (TACE) to yield a membrane-associated intermediate fragment called notch extracellular truncation (NEXT). This fragment is then cleaved by presenilin dependent gamma-secretase to release a notch-derived peptide containing the intracellular domain (NICD) from the membrane. Defects in NOTCH3 are the cause of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). CADASIL causes a type of stroke and dementia of which key features include recurrent subcortical ischemic events and vascular dementia. The disorder affects relatively young adults of both sexes.
Pathways Notch Signaling
Restrictions For Research Use only
Product cited in: Wu, Sun, Kobayashi, Gao, Griffin: "Identification of a family of mastermind-like transcriptional coactivators for mammalian notch receptors." in: Molecular and cellular biology, Vol. 22, Issue 21, pp. 7688-700, 2002 (PubMed).

Gray, Mann, Mitsiadis, Henrique, Carcangiu, Banks, Leiman, Ward, Ish-Horowitz, Artavanis-Tsakonas: "Human ligands of the Notch receptor." in: The American journal of pathology, Vol. 154, Issue 3, pp. 785-94, 1999 (PubMed).

Joutel, Corpechot, Ducros, Vahedi, Chabriat, Mouton, Alamowitch, Domenga, Cécillion, Marechal, Maciazek, Vayssiere, Cruaud, Cabanis, Ruchoux, Weissenbach, Bach, Bousser, Tournier-Lasserve: "Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia." in: Nature, Vol. 383, Issue 6602, pp. 707-10, 1996 (PubMed).